Sanofi (SNYNF)
| Market Cap | 116.94B |
| Revenue (ttm) | 53.89B |
| Net Income (ttm) | 10.69B |
| Shares Out | n/a |
| EPS (ttm) | 8.67 |
| PE Ratio | 10.94 |
| Forward PE | 9.98 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 344 |
| Average Volume | 19,623 |
| Open | 95.28 |
| Previous Close | 96.47 |
| Day's Range | 95.28 - 95.28 |
| 52-Week Range | 90.05 - 122.03 |
| Beta | 0.37 |
| RSI | 44.78 |
| Earnings Date | Jan 29, 2026 |
About Sanofi
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases, neurology, oncology, and other medicines and vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines protecting against diphtheria, tetanus, pertussis, polio, Hib, and hepatitis B; influenza, booster, meningitis, and travel and endemic vaccines, that includes hepati... [Read more]
Financial Performance
In 2024, Sanofi's revenue was 44.29 billion, an increase of 7.73% compared to the previous year's 41.11 billion. Earnings were 5.56 billion, an increase of 2.96%.
Financial numbers in EUR Financial StatementsNews
Dynavax Technologies (DVAX) Shares Are Trending Overnight — Here's Why
Dynavax Technologies Corporation (NASDAQ: DVAX) shares are trending on Thursday. Check out the current price of DVAX stock here . Shares of the California-based biopharmaceutical company surged 38.19...
What Sanofi Is Getting Through The Acquisition Of Dynavax
Sanofi to Acquire Dynavax, Expanding Vaccine Portfolio
Sanofi to Acquire Dynavax, Expanding Vaccine Portfolio
FDA Issues CRL to SNY's Regulatory Filing for Multiple Sclerosis Drug
Sanofi receives an FDA CRL for tolebrutinib in nrSPMS after multiple review extensions. The EC clears Wayrilz for treating immune thrombocytopenia.
Sanofi to Buy Dynavax for $2.2B to Boost Adult Vaccine Franchise
SNY's $2.2 billion deal for Dynavax adds Heplisav-B, a shingles candidate, and other vaccine programs, strengthening its adult vaccine franchise and pipeline.
Sanofi Agrees to Buy Dynavax for $2.2 Billion After FDA MS Drug Rejection
Sanofi Agrees to Buy Dynavax for $2.2 Billion After FDA MS Drug Rejection
Sanofi to Acquire Dynavax for $2.2 Billion, Expanding Vaccine Portfolio
Sanofi to Acquire Dynavax for $2.2 Billion, Expanding Vaccine Portfolio
This Biotech Stock Is Soaring. Sanofi Is Buying It for $2.2 Billion.
Sanofi (SNY) Faces FDA Rejection for Tolebrutinib in MS Treatment
Sanofi (SNY) Faces FDA Rejection for Tolebrutinib in MS Treatment
Sanofi multiple sclerosis therapy rejected by the FDA
Sanofi (SNY) stock is in focus as the company agrees to acquire Dynavax Technologies (DVAX) and the FDA rejects its multiple sclerosis drug tolebrutinib. Read more here.
Sanofi (SNY) Proposes Acquisition of Dynavax, Boosting Stock Value
Sanofi (SNY) Proposes Acquisition of Dynavax, Boosting Stock Value
Sanofi To Buy Vaccine Maker Dynavax for $2.2 Billion
Sanofi will buy vaccine maker Dynavax Technologies for $2.2 billion, or $15.50 a share, adding to its adult immunizations. Dynavax stock soared.
Sanofi Makes $2.2 Billion Bet On Adult Vaccines With Dynavax Buy
Sanofi SA (NASDAQ: SNY) on Wednesday agreed to acquire Dynavax Technologies Corporation (NASDAQ: DVAX) for $15.50 per share in cash, reflecting a total equity value of approximately $2.2 billion. Th...
Sanofi to Acquire Dynavax Technologies (DVAX) for $2.2 Billion
Sanofi to Acquire Dynavax Technologies (DVAX) for $2.2 Billion
Biggest stock movers Wednesday: DVAX, NKE, and more
Get the latest stock market movers: Dynavax surges on Sanofi acquisition, UiPath gains on S&P MidCap 400 entry.
Sanofi to acquire US biotech Dynavax for $2.2 billion
French drugmaker Sanofi has entered into an agreement to acquire U.S. vaccines company Dynavax Technologies Corporation for around $2.2 billion (1.87 billion euros), it said on Wednesday.
Sanofi (SNY) to Acquire Dynavax (DVAX) for $2.2 Billion
Sanofi (SNY) to Acquire Dynavax (DVAX) for $2.2 Billion
Sanofi to buy Dynavax for $15.50 per share
Sanofi to Buy Vaccine Maker Dynavax in $2.2 Billion Deal
The cash deal seeks to strengthen the French drugmaker's immunization portfolio after it suffered setbacks in clinical trials.
Sanofi To Commence Cash Tender Offer To Acquire Dynavax For $15.50/share
(RTTNews) - Sanofi (SNY, SAN.PA) has entered into an agreement to acquire Dynavax Technologies, a publicly traded vaccines company with a marketed adult hepatitis B vaccine and differentiated shingles...
FDA Issues Complete Response Letter For Sanofi's Tolebrutinib In NrSPMS Review
(RTTNews) - Sanofi (SNY, SAN.PA) announced that the U.S. Food and Drug Administration has issued a complete response letter (CRL) for the new drug application of tolebrutinib to treat non-relapsing se...
Press Release: Sanofi to acquire Dynavax, adding a marketed adult hepatitis B vaccine and phase 1/2 shingles candidate to the pipeline
Sanofi to acquire Dynavax, adding a marketed adult hepatitis B vaccine and phase 1/2 shingles candidate to the pipeline Paris, December 24, 2025. Sanofi announced today that it has entered into an agr...
Press Release: Sanofi provides update on tolebrutinib regulatory submission in non-relapsing secondary progressive multiple sclerosis
Sanofi provides update on tolebrutinib regulatory submission in non-relapsing secondary progressive multiple sclerosis Paris, December 24, 2025. The US Food and Drug Administration (FDA) has issued a ...
Sanofi Wins EU Approval For Wayrilz In Immune Thrombocytopenia
(RTTNews) - Sanofi SA (SNY) on Tuesday said that the European Commission has given the green light to Wayrilz or rilzabrutinib for treating immune thrombocytopenia in adults who haven't had success wi...
Press Release: Sanofi's Wayrilz approved in the EU as the first BTK inhibitor to treat immune thrombocytopenia
Sanofi's Wayrilz approved in the EU as the first BTK inhibitor to treat immune thrombocytopenia Novel treatment targets BTK through multi-immune modulation to help address the underlying causes of ITP...